ストックスクリーナーアプリを入手
3.58
10.95%
-0.44
アフターアワーズ：
3.50
-0.08
-2.23%
前日終値:
$4.02
開ける：
$4.03
24時間の取引高:
301.74K
Relative Volume:
1.49
時価総額：
$117.15M
収益：
$1.95M
当期純損益:
$-47.84M
株価収益率:
-2.4137
EPS:
-1.4832
ネットキャッシュフロー:
$-27.46M
1週間 パフォーマンス:
-12.68%
1か月 パフォーマンス:
-17.13%
6か月 パフォーマンス:
-21.15%
1年 パフォーマンス:
+4.07%
1日の値動き範囲:
$3.50
$4.205
1週間の範囲:
$3.50
$4.24
52週間の値動き範囲:
$2.42
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
名前
Insight Molecular Diagnostics Inc
セクター
電話
949-409-7600
住所
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, NTRA, IQV, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.58 | 137.44M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
Insight Molecular Diagnostics Inc (IMDX) 最新ニュース
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Medicare policy boosts iMDx transplant testing frequency - scanx.trade
Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et
iMDx executives are set to meet investors in New York - Stock Titan
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference - GlobeNewswire
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria
Insight Molecular Q2FY26 Results: Cash burn rises to $10 million - scanx.trade
Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn
Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics advances heart tr... - Pluang
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Rest-Of-Europe Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - marketsandmarkets.com
Insight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform - scanx.trade
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com Nigeria
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com
Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa
Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com
IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila Times
IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 55% EPS SurpriseProfit Guidance Range - vinanet.vn
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in FocusVolatility Smirk - vinanet.vn
IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Earnings Preview: IMDX to Report Financial Results Post-market on August 10 - Moomoo
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - The Manila Times
IMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - marketscreener.com
iMDx to Release Second Quarter Results on August 10, 2026 - GlobeNewswire
iMDx to report Q2 2026 results on Aug 10 and jo... - Pluang
IMDX Rises 1.09% to $4.65 as Molecular Diagnostics Play Holds Key SupportPoint of Control - vinanet.vn
IMDX Q1 2026 Earnings: Narrower Loss Beats Consensus, Shares Gain 1.09%Earnings Seasonality - vinanet.vn
Insight Molecular Diagnostics Inc (IMDX) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
大文字化:
|
ボリューム (24 時間):